NRX Pharmaceuticals, Inc. (NRXP) stock
NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.45+0.30 (+13.95%)
Close on Nov 17, 2026Market cap $106.08MP/E –Yield –
NRX Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
NRX Pharmaceuticals's cash was $26.69M at Jun 30, 2026. For fiscal 2025 it was $7.80M, up 440.3% from the year before. The highest annual figure on record is $27.61M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.80M | +440.3% |
| FY2024 | Dec 31, 2024 | $1.44M | -68.6% |
| FY2023 | Dec 31, 2023 | $4.60M | -77.1% |
| FY2022 | Dec 31, 2022 | $20.05M | -27.4% |
| FY2021 | Dec 31, 2021 | $27.61M | +1384.9% |
| FY2020 | Dec 31, 2020 | $1.86M | +111.9% |
| FY2019 | Dec 31, 2019 | $877.42K | +7819.7% |
| FY2018 | Dec 31, 2018 | $11.08K | -97.5% |
| FY2017 | Dec 31, 2017 | $449.37K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $26.69M | +817.0% |
| Q1 FY2026 | Mar 31, 2026 | $6.71M | +21.0% |
| Q4 FY2025 | Dec 31, 2025 | $7.80M | +440.3% |
| Q3 FY2025 | Sep 30, 2025 | $7.18M | +336.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.91M | +53.3% |
| Q1 FY2025 | Mar 31, 2025 | $5.55M | +320.6% |
| Q4 FY2024 | Dec 31, 2024 | $1.44M | -68.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.65M | -81.5% |
| Q2 FY2024 | Jun 30, 2024 | $1.90M | -87.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.32M | -92.0% |
| Q4 FY2023 | Dec 31, 2023 | $4.60M | -77.1% |
| Q3 FY2023 | Sep 30, 2023 | $8.90M | -51.2% |
| Q2 FY2023 | Jun 30, 2023 | $14.97M | -39.0% |
| Q1 FY2023 | Mar 31, 2023 | $16.51M | -58.9% |
| Q4 FY2022 | Dec 31, 2022 | $20.05M | -27.4% |
| Q3 FY2022 | Sep 30, 2022 | $18.25M | -53.1% |
| Q2 FY2022 | Jun 30, 2022 | $24.55M | +83.4% |
| Q1 FY2022 | Mar 31, 2022 | $40.20M | +202.9% |
| Q4 FY2021 | Dec 31, 2021 | $27.61M | +1384.9% |
| Q3 FY2021 | Sep 30, 2021 | $38.88M | +2919.5% |
| Q2 FY2021 | Jun 30, 2021 | $13.39M | +1244.0% |
| Q1 FY2021 | Mar 31, 2021 | $13.27M | +16329.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.86M | +111.9% |
| Q3 FY2020 | Sep 30, 2020 | $1.29M | +562.8% |
| Q2 FY2020 | Jun 30, 2020 | $995.99K | +71348.0% |
| Q1 FY2020 | Mar 31, 2020 | $80.77K | +4343.0% |
| Q4 FY2019 | Dec 31, 2019 | $877.42K | +7819.7% |
| Q3 FY2019 | Sep 30, 2019 | $194.28K | +152.0% |
| Q2 FY2019 | Jun 30, 2019 | $1.39K | -99.0% |
| Q1 FY2019 | Mar 31, 2019 | $1.82K | -99.3% |
| Q4 FY2018 | Dec 31, 2018 | $11.08K | -97.5% |
| Q3 FY2018 | Sep 30, 2018 | $77.09K | – |
| Q2 FY2018 | Jun 30, 2018 | $139.61K | – |
| Q1 FY2018 | Mar 31, 2018 | $267.19K | – |
| Q4 FY2017 | Dec 31, 2017 | $449.37K | – |
| Q3 FY2017 | Sep 17, 2017 | $0 | – |
See a number that looks wrong?